Risedronic acid

Absorption

Oral bioavailability is 0.63% and maximum absorption is approximately 1 hour after dosing. Administration half and hour before a meal reduces bioavailability by 55% compared to fasting and dosing 1 hour before a meal reduces bioavailability by 30%.

Toxicity

In clinical trials, over 10% of patients experienced back pain, arthralgia, abdominal pain, and dyspepsia. Less commonly, patients experience angioedema, generalized rash, bullous skin reactions, iritis, and uveitis.
Patients experiencing an overdose may experience a decrease in serum calcium and phosphorus. Patients can be given milk or antacids to bind the drug and reduce its absorption. In more severe cases, patients may require gastric lavage and intravenous calcium. A lethal dose in rats is equivalent to 320 to 620 times the human dose based on surface area.

The Uses of Risedronic acid

Risedronic Acid is a pyridinyl biphosphonate bone resorption inhibitor. It is a potentially useful biophosphonate for bone resorption analysis.

What are the applications of Application

Risedronic acid is a potentially useful biophosphonate for bone resorption analysis

Indications

Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis.

Background

Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Definition

ChEBI: Risedronic acid is a member of pyridines. It is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Pharmacokinetics

Risedronate is a pyridine-based bisphosphonate that inhibits bone resorption caused by osteoclasts.

Metabolism

Risedronic acid is not likely not metabolized before elimination. The P-C-P group of bisphosphonates is resistant to chemical and enzymatic hydrolysis preventing metabolism of the molecule.

Mode of action

Risedronatic acid binds to bone hydroxyapatite. Bone resorption causes local acidification, releasing risedronic acid which is that taken into osteoclasts by fluid-phase endocytosis. Endocytic vesicles are acidified, releasing risedronic acid to the cytosol of osteoclasts where they induce apoptosis through inhbition of farnesyl pyrophosphate synthase. Inhibition of osteoclasts results in decreased bone resorption.